• Cannabis Terpenes Relieve Neuropathic Pain via A2A Receptor

  2026-08-01

  Schwarz et al. reveal that multiple terpenes from Cannabis sativa produce robust antinociception in mouse models of chronic neuropathic pain through selective activation of adenosine A2A receptors. This mechanism is independent of cannabinoid pathways, providing a new direction for non-rewarding analgesic research and broadening the landscape of phytochemical pain modulation.

• Azithromycin and Roxithromycin as Selective Senolytics in Hu

  2026-07-31

  Ozsvari et al. (2018) systematically identified azithromycin and roxithromycin as novel senolytic agents that selectively target senescent human fibroblasts, sparing non-senescent cells. Their work establishes a practical drug repurposing pipeline for screening senolytic activity and illuminates key metabolic effects underlying antibiotic-induced senescence clearance.

• Coumestrol Induces Ferroptosis in RA-FLS via PMAIP1 Stabiliz

  2026-07-31

  This study demonstrates that coumestrol, a phytoestrogen estrogen receptor antagonist, induces ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS) by stabilizing mitochondrial PMAIP1 through inhibition of TRIM3-mediated degradation. These findings suggest a novel mechanism by which coumestrol may suppress pathological proliferation and inflammation in RA, supporting further investigation into its therapeutic potential.

• Dual Metabolic Reprogramming Enhances Ferroptosis in TNBC

  2026-07-30

  This study introduces a metal-polyphenol nanoplatform that co-targets GPX4 and DHODH while remodeling lipid metabolism to overcome ferroptosis resistance in triple-negative breast cancer (TNBC). The dual metabolic approach demonstrates increased ferroptotic sensitivity and therapeutic efficacy in vitro and in vivo, providing new insights for advancing combinatorial cancer therapies.

• Magnetic Stimulation Downregulates GABRE to Reverse Schizoph

  2026-07-30

  This study demonstrates that targeted magnetic stimulation of the left prelimbic cortex in mice downregulates the GABAA receptor epsilon subunit, effectively reversing schizophrenia-like behaviors and synaptic deficits. The findings reveal a mechanistic pathway for noninvasive neuromodulation and highlight GABRE as a promising therapeutic target for negative and cognitive symptoms in schizophrenia.

• Merimepodib (VX-497): Protocol-Driven IMPDH Inhibition in An

  2026-07-29

  Merimepodib (VX-497) stands out as a selective, noncompetitive IMPDH inhibitor, enabling researchers to dissect guanine nucleotide biosynthesis in virology, immunology, and oncology. Its robust activity against both viral replication and lymphocyte proliferation unlocks translational workflows that bridge fundamental biochemistry with disease modeling.

• tFUS Attenuates Stroke Neuroinflammation via Nespas/miR-383-

  2026-07-29

  This study demonstrates that transcranial focused ultrasound stimulation (tFUS) reduces neuroinflammation after ischemic stroke by modulating the Nespas/miR-383-3p/SHP2 signaling axis in microglia. The findings offer mechanistic insight into noninvasive neuromodulation as a strategy for targeting SHP2-driven inflammasome activity, opening avenues for refined research on neuroinflammatory modulation.

• Aminocoumarin Probe Illuminates HO-1 Regulation in Macrophag

  2026-07-28

  The reference study introduces AMC-Hem, a red-shifted aminocoumarin-based fluorescent probe that enables real-time imaging of heme oxygenase-1 (HO-1) activity in live human macrophages. This work reveals spatial organization of HO-1 at lysosomal membranes and uncovers non-transcriptional regulatory mechanisms, advancing our understanding of vascular inflammation and potential diagnostic applications.

• SP2509 and the Epigenetic Reset: Advanced Strategies in AML

  2026-07-28

  Explore how SP2509, a potent Lysine-specific demethylase 1 antagonist, enables advanced control of cancer epigenetics in acute myeloid leukemia. This deep-dive article uniquely connects SP2509’s molecular pharmacology to next-generation assay design and cross-talk with chromatin-modifying therapies.

• HAUS1 Expression and Immune Microenvironment in HCC: Insight

  2026-07-27

  This study elucidates the prognostic significance of HAUS1 in hepatocellular carcinoma (HCC) and its relationship with the immune microenvironment. Through integrative bioinformatics and in vitro experiments, the research demonstrates that HAUS1 is not only a diagnostic and prognostic biomarker but also a potential therapeutic target in HCC.

• JNJ-26481585 (Quisinostat): Advanced HDAC Inhibitor for Tumo

  2026-07-27

  JNJ-26481585 (Quisinostat) offers translational researchers a potent, precision-targeted HDAC inhibitor for overcoming tumor resistance, particularly through TRIM21 downregulation. This guide demystifies experimental setup, workflow optimization, and troubleshooting, leveraging the latest mechanistic findings and practical data from leading studies.

• Mitoxantrone HCl: Applied Protocols for DNA Topoisomerase II

  2026-07-26

  Mitoxantrone HCl stands out not only as a DNA topoisomerase II inhibitor but as a versatile tool for probing apoptosis, cancer resistance mechanisms, and nuclear receptor modulation. This article delivers actionable workflows and troubleshooting strategies for leveraging Mitoxantrone HCl in advanced cell and animal model research, spotlighting recent breakthroughs in allosteric estrogen receptor targeting.

• Sphingosine-1-phosphate: Translational Leverage for Apoptosi

  2026-07-25

  This article explores how sphingosine-1-phosphate (S1P) orchestrates cell survival, apoptosis, and vascular dynamics, integrating mechanistic insights with strategic advice for translational researchers. Anchored by the latest reference findings on S1P/S1PR3-driven neuronal apoptosis and competitive assay guidance, it highlights the clinical and experimental relevance of S1P, including workflow parameters for rigorous study design. Distinguishing itself from standard product literature, this piece uniquely bridges emerging neurovascular mechanisms to applied research opportunities.

• Fenofibrate as a PPARα Agonist: Experimental Workflows & Ins

  2026-07-24

  Fenofibrate, a benchmark PPARα agonist from APExBIO, enables precise dissection of lipid metabolism and signaling pathways in both standard and aging research models. This guide translates cutting-edge findings on the PPARα-YAP axis into actionable protocols, troubleshooting, and comparative strategies for robust, reproducible experiments.

• TRIB3 Knockdown Sensitizes ccRCC to Sunitinib via Ferroptosi

  2026-07-24

  This study demonstrates that TRIB3 knockdown in clear cell renal cell carcinoma (ccRCC) cells enhances their sensitivity to sunitinib by promoting ferroptosis through the SLC7A11/GPX4 pathway. These findings provide mechanistic insight into sunitinib resistance and suggest new strategies for improving targeted therapy outcomes in ccRCC.

446 records 9/30 page Previous Next First page 上5页 678910 下5页 Last page